

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 August 2016



Contents

Summary of decisions effective 1 August 2016.....	3
Section H changes to Part II	6
Index.....	12

Summary of decisions

EFFECTIVE 1 AUGUST 2016

- Aciclovir (ViruPOS) eye oint 3%, 4.5 g – new listing and addition of HSS
- Alendronate sodium with colecalciferol (Fosamax Plus) tab 70 mg with colecalciferol 5,600 iu – chemical name and presentation description amended
- Amiodarone hydrochloride (Cordarone X) tab 100 mg and 200 mg – new listing and addition of HSS
- Amisulpride (Solian) oral liq 100 mg per ml – price increase and addition of HSS
- Beclomethasone dipropionate (Alanase) nasal spray 50 mcg per dose and 100 mcg per dose – price increase
- Budesonide (Betacort Aqueous) nasal spray 50 mcg per dose and 100 mcg per dose – price increase
- Cefalexin (Cephalexin ABM) cap 500 mg – price increase and addition of HSS
- Colecalciferol (Vit.D3) cap 1.25 mg (50,000 iu) – amended chemical name
- Dacarbazine (DBL Dacarbazine) inj 200 mg vial – price increase, addition of HSS and amended brand name
- Dothiepin hydrochloride (Dopress) tab 75 mg and cap 25 mg – price increase
- Ferrous sulphate (Ferodan) oral liq 30 mg (6 mg elemental) per ml – price increase and addition of HSS
- Fluoxetine hydrochloride (Arrow-Fluoxetine) tab dispersible 20 mg, scored – price decrease and addition of HSS
- Fluoxetine hydrochloride (Arrow-Fluoxetine) cap 20 mg – price increase and addition of HSS
- Haloperidol (Serenace) tab 500 mcg, 1.5 mg and 5 mg, oral liq 2 mg per ml and inj 5 mg per ml, 1 ml ampoule – addition of HSS
- High arginine oral feed 1.4 kcal/ml (Impact Advanced Recovery) liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton, 178 ml – new listing
- High arginine oral feed 1.4 kcal/ml (Impact Advanced Recovery (Chocolate and Vanilla) liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton, 237 ml – to be delisted 1 February 2017
- Hydrocortisone (Solu-Cortef) inj 100 mg vial – price increase and addition of HSS
- Indapamide (Dapa-Tabs) tab 2.5 mg – price increase and addition of HSS
- Isosorbide mononitrate (Duride) tab long-acting 60 mg – price increase
- Labetalol (Hybloc) tab 50 mg, 100 mg and 200 mg – price increase

Summary of decisions – effective 1 August 2016 (continued)

- Levonorgestrel (Mirena) intra-uterine system, 20 mcg per day – new listing and addition of HSS
 - Loperamide hydrochloride (Nodia) tab 2 mg – new listing and addition of HSS
 - Medroxyprogesterone acetate (Depo-Provera) inj 150 mg per ml, 1 ml syringe – price increase and addition of HSS
 - Medroxyprogesterone acetate (Provera) tab 2.5 mg, 5 mg and 10 mg – price increase and addition of HSS
 - Medroxyprogesterone acetate (Provera HD) tab 100 mg – price increase, addition of HSS and amended brand name
 - Mesna (Uromitexan) tab 400 mg and 600 mg – price increase and addition of HSS
 - Mesna (Uromitexan) inj 100 mg per ml, 4 ml and 10 ml ampoules – price increase and addition of HSS
 - Methotrexate (DBL Methotrexate Onco-Vial) inj 25 mg per ml, 2 ml and 20 ml vials – price increase, addition of HSS and amended brand name
 - Metoprolol succinate (Metoprolol – AFT CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg – HSS delayed until 1 January 2017
 - Mitomycin C (Arrow) inj 5 mg vial – price increase and addition of HSS
 - Morphine tartrate (DBL Morphine Tartrate) inj 80 mg per ml, 1.5 ml ampoule – price increase, addition of HSS and amended brand name
 - Nevirapine (Viramune Suspension) oral suspension 10 mg per ml – price increase
 - Oestradiol (Estradot) patch 25 mcg, 50 mcg and 100 mcg per day – new listing and addition of HSS
 - Ondansetron (Ondansetron Kabi) inj 2 mg per ml, 4 ml ampoule – HSS delayed until 1 November 2016
 - Ondansetron (Ondanaccord) inj 2 mg per ml, 4 ml ampoule – delisting to be delayed until 1 November 2016
 - Ornidazole (Arrow-Ornidazole) tab 500 mg – price increase and addition of HSS
 - Penicillamine (D-Penammine) tab 125 mg and 250 mg – price increase
 - Promethazine hydrochloride (Hospira) inj 25 mg per ml, 2 ml ampoule – price increase and addition of HSS
 - Progesterone (Utragestan) cap 100 mg – amended restriction
 - Quinine sulphate (Q 300) tab 300 mg – price increase
 - Rifabutin (Mycobutin) cap 150 mg – price increase and addition of HSS
-

Summary of decisions – effective 1 August 2016 (continued)

- Sodium chloride (Biomed) inj 23.4% (4mmol/ml), 20 ml ampoule – amended presentation description, price increase and addition of HSS
- Sotalol (Mylan) tab 80 mg and 160 mg – price increase and addition of HSS
- Spironolactone (Spiractin) tab 25 mg – price increase and addition of HSS
- Spironolactone (Spiractin) tab 100 mg – addition of HSS
- Sulphasalazine tab 500 mg (Salazopyrin) and tab EC 500 mg (Salazopyrin EN) – price increase and addition of HSS
- Temozolomide (Temaccord) cap 5 mg, 20 mg, 100 mg and 250 mg – amended restriction
- Vincristine sulphate (DBL Vincristine Sulfate) inj 1 mg per ml, 1 ml and 2 ml vials – price increase, addition of HSS and amended brand name

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 August 2016

ALIMENTARY TRACT AND METABOLISM

13	LOPERAMIDE HYDROCHLORIDE (new listing) Tab 2 mg – 1% DV Oct-16 to 2019	10.75	400	Nodia
14	SULPHASALAZINE (↑ price and addition of HSS) Tab 500 mg – 1% DV Oct-16 to 2019	14.00	100	Salazopyrin
	Tab EC 500 mg – 1% DV Oct-16 to 2019	13.50	100	Salazopyrin EN
23	FERROUS SULPHATE (↑ price and addition of HSS) Oral liq 30 mg (6 mg elemental) per ml – 1% DV Oct-16 to 2019	10.80	500 ml	Ferodan
26	COLECALCIFEROL CHOLECALCIFEROL (amended chemical name) Cap 1.25 mg (50,000 iu)	3.85	12	Vit.D3

BLOOD AND BLOOD FORMING ORGANS

38	SODIUM CHLORIDE (amended presentation description, ↑ price and addition of HSS) Inj 23.4% (4 mmol/ml), 20 ml ampoule – 1% DV Oct-16 to 2019	33.00	5	Biomed
----	---	-------	---	--------

CARDIOVASCULAR SYSTEM

43	AMIODARONE HYDROCHLORIDE (new listing) Tab 100 mg – 1% DV Oct-16 to 2019	4.66	30	Cordarone X
	Tab 200 mg – 1% DV Oct-16 to 2019	7.63	30	Cordarone X
44	LABETALOL (↑ price) Tab 50 mg	8.99	100	Hybloc
	Tab 100 mg	11.36	100	Hybloc
	Tab 200 mg	29.74	100	Hybloc
44	METOPROLOL SUCCINATE (HSS delayed) Tab long-acting 23.75 mg – 1% DV Nov-16 Jan-17 to 2018	2.39	90	Metoprolol - AFT CR
	Tab long-acting 47.5 mg – 1% DV Nov-16 Jan-17 to 2018	3.48	90	Metoprolol - AFT CR
	Tab long-acting 95 mg – 1% DV Nov-16 Jan-17 to 2018	5.73	90	Metoprolol - AFT CR
	Tab long-acting 190 mg – 1% DV Nov-16 Jan-17 to 2018	11.54	90	Metoprolol - AFT CR
45	SOTALOL (↑ price and addition of HSS) Tab 80 mg – 1% DV Oct-16 to 2019	39.53	500	Mylan
	Tab 160 mg – 1% DV Oct-16 to 2019	12.48	100	Mylan
47	INDAPAMIDE (↑ price and addition of HSS) Tab 2.5 mg – 1% DV Oct-16 to 2019	2.60	90	Dapa-Tabs
47	SPIRONOLACTONE (addition of HSS) Tab 25 mg – 1% DV Oct-16 to 2019 (↑ price)	4.38	100	Spiractin
	Tab 100 mg – 1% DV Oct-16 to 2019	11.80	100	Spiractin

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2016 (continued)

49	ISOSORBIDE MONONITRATE († price) Tab long-acting 60 mg	8.49	90	Duride
----	---	------	----	--------

GENITO-URINARY SYSTEM

60	LEVONORGESTREL (new listing) → Intra-uterine system, 20 mcg per day – 1% DV Aug-16 to 2019	269.50	1	Mirena e.g. Mirena
60	MEDROXYPROGESTERONE ACETATE († price and addition of HSS) Inj 150 mg per ml, 1 ml syringe – 1% DV Oct-16 to 2019	7.25	1	Depo-Provera

61	PROGESTERONE (amended restriction) → Cap 100 mg – 1% DV Aug-16 to 2019	16.50	30	Utrogestan
Restricted Initiation Gynaecologist or obstetrician Re-assessment required after 12 months Both: 1 For the prevention of pre-term labour*; and 2 Either: 2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or 2.2 The patient has a history of pre-term birth at less than 28 weeks.				

Continuation

Gynaecologist or obstetrician

Re-assessment required after 12 months

All of the following:

1. For the prevention of pre-term labour*; and
2. Treatment is required for second or subsequent pregnancy; and
3. Either:
 - 3.1. The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
 - 3.2. The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1)

HORMONE PREPARATIONS

64	HYDROCORTISONE († price and addition of HSS) Inj 100 mg vial – 1% DV Oct-16 to 2019	5.30	1	Solu-Cortef
66	MEDROXYPROGESTERONE ACETATE († price and addition of HSS) Tab 2.5 mg – 1% DV Oct-16 to 2019	3.75	30	Provera
	Tab 5 mg – 1% DV Oct-16 to 2019	14.00	100	Provera
	Tab 10 mg – 1% DV Oct-16 to 2019	7.15	30	Provera

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2016 (continued)

65	OESTRADIOL (new listing)			
	Patch 25 mcg per day – 1% DV Oct-16 to 2019	6.12	8	Estradot
	Patch 50 mcg per day – 1% DV Oct-16 to 2019	7.04	8	Estradot
	Patch 100 mcg per day – 1% DV Oct-16 to 2019	7.91	8	Estradot
66	MEDROXYPROGESTERONE (↑ price, addition of HSS and amended brand name)			
	Tab 100 mg – 1% DV Oct-16 to 2019	101.00	100	Provera HD Provera

INFECTIONS

74	CEFALEXIN (↓ price and addition of HSS)			
	Cap 500 mg – 1% DV Oct-16 to 2019	3.95	20	Cephalexin ABM
83	RIFABUTIN (↑ price and addition of HSS)			
	→ Cap 150 mg – 1% DV Oct-16 to 2019	275.00	30	Mycobutin
84	ORNIDAZOLE (↑ price and addition of HSS)			
	Tab 500 mg – 1% DV Oct-16 to 2019	23.00	10	Arrow-Ornidazole
85	Quinine sulphate (↑ price)			
	Tab 300 mg	61.91	500	Q 300
86	NEVIRAPINE (↑ price)			
	→ Oral suspension 10 mg per ml.....	203.55	240 ml	Viramune Suspension

MUSCULOSKELETAL SYSTEM

97	PENICILLAMINE (↑ price)			
	Tab 125 mg	67.23	100	D-Penaminate
	Tab 250 mg	110.12	100	D-Penaminate
98	ALENDRONATE SODIUM WITH COLECALCIFEROL CHOLECALCIFEROL (chemical name and presentation description amendment)			
	→ Tab 70 mg with colecalfiferol cholecalciferol 5,600 iu.....	12.90	4	Fosamax Plus

NERVOUS SYSTEM

113	MORPHINE TARTRATE (↑ price, addition of HSS and amended brand name)			
	Inj 80 mg per ml, 1.5 ml ampoule – 1% DV Oct-16 to 2019	42.72	5	DBL Morphine Tartrate Hospira
115	DOTHIPIIN HYDROCHLORIDE (↑ price)			
	Tab 75 mg	11.19	100	Dopress
	Cap 25 mg	6.45	100	Dopress
116	FLUOXETINE HYDROCHLORIDE (addition of HSS)			
	Tab dispersible 20 mg, scored			
	– 1% DV Oct-16 to 2019 (↓ price)	2.47	30	Arrow-Fluoxetine
	Cap 20 mg – 1% DV Oct-16 to 2019 (↑ price)	1.99	90	Arrow-Fluoxetine

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

Changes to Section H Part II – effective 1 August 2016 (continued)

123	AMISULPRIDE (↑ price and addition of HSS) Oral liq 100 mg per ml – 1% DV Oct-16 to 2019	65.53	60 ml	Solian
123	ONDANSETRON (HSS and delisting delayed) Inj 2 mg per ml, 4 ml ampoule – 1% DV Nov-16 Sep-16 to 2019	2.20	5	Ondansetron Kabi
Note – HSS for Ondansetron-Kabi has been delayed and will now begin from 1 November 2016. The delisting of Ondanaccord inj 2 mg per ml, 4 ml ampoule will also be delayed until 1 November 2016.				
124	HALOPERIDOL (addition of HSS) Tab 500 mcg – 1% DV Oct-16 to 2019	6.23	100	Serenace
	Tab 1.5 mg – 1% DV Oct-16 to 2019	9.43	100	Serenace
	Tab 5 mg – 1% DV Oct-16 to 2019	29.72	100	Serenace
	Oral liq 2 mg per ml – 1% DV Oct-16 to 2019	23.84	100 ml	Serenace
	Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-16 to 2019	21.55	10	Serenace

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

135	MITOMYCIN C (↑ price and addition of HSS) Inj 5 mg vial – 1% DV Oct-16 to 2019	204.08	1	Arrow
136	METHOTREXATE (↑ price, addition of HSS and amended brand name) Inj 25 mg per ml, 2 ml vial – 1% DV Oct-16 to 2019	30.00	5	DBL Methotrexate Onco-Vial Hospira
	Inj 25 mg per ml, 20 ml vial – 1% DV Oct-16 to 2019	45.00	1	DBL Methotrexate Onco-Vial Hospira
137	DACARBAZINE (↑ price, addition of HSS and amended brand name) Inj 200 mg vial – 1% DV Oct-16 to 2019	58.06	1	DBL Decarbazine Hospira
138	TEMOZOLOMIDE (amended restriction) → Cap 5 mg.....	8.00	5	Temaccord
	→ Cap 20 mg.....	36.00	5	Temaccord
	→ Cap 100 mg.....	175.00	5	Temaccord
	→ Cap 250 mg.....	410.00	5	Temaccord

Restricted

Initiation – High grade gliomas

All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Initiation – Neuroendocrine tumours

Re-assessment required after 9 months

All of the following:

1. Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*;
and
2. Temozolomide is to be given in combination with capecitabine; and

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2016 (continued)

continued...

3. Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
4. Temozolomide to be discontinued at disease progression.

Continuation – Neuroendocrine tumours

Re-assessment required after 6 months

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an Unapproved Indication. Temozolomide is not funded for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >= 80), and in patients who have had at least a partial resection of the tumour.

144	MESNA (↑ price and addition of HSS)			
	Tab 400 mg – 1% DV Oct-16 to 2019	273.00	50	Uromitexan
	Tab 600 mg – 1% DV Oct-16 to 2019	407.50	50	Uromitexan
	Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-16 to 2019	161.37	15	Uromitexan
	Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-16 to 2019	370.49	15	Uromitexan
144	VINCRIStINE SULPHATE (↑ price, addition of HSS and amended brand name)			
	Inj 1 mg per ml, 1 ml vial – 1% DV Oct-16 to 2019	74.52	5	DBL Vincristine Sulfate Hospira
	Inj 1 mg per ml, 2 ml vial – 1% DV Oct-16 to 2019	85.61	5	DBL Vincristine Sulfate Hospira

RESPIRATORY SYSTEM AND ALLERGIES

180	BECLOMETHASONE DIPROPIONATE (↑ price)			
	Nasal spray 50 mcg per dose	5.26	200 dose	Alanase
	Nasal spray 100 mcg per dose	6.00	200 dose	Alanase
181	BUDESONIDE (↑ price)			
	Nasal spray 50 mcg per dose	5.26	200 dose	Butacort Aqueous
	Nasal spray 100 mcg per dose	6.00	200 dose	Butacort Aqueous
181	PROMETHAZINE HYDROCHLORIDE (↑ price and addition of HSS)			
	Inj 25 mg per ml, 2 ml ampoule – 1% DV Oct-16 to 2019	15.54	5	Hospira

SENSORY ORGANS

187	ACICLOVIR (new listing)			
	Eye oint 3% – 1% DV Oct-16 to 2019	14.92	4.5 g	ViruPOS

SPECIAL FOODS

216	HIGH ARGININE ORAL FEED 1.4 KCAL/ML (new listing)			
	→ Liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton	4.00	178 ml	Impact Advanced Recovery

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2016 (continued)

216	HIGH ARGININE ORAL FEED 1.4 KCAL/ML (delisting)			
	→ Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton	4.00	237 ml	Impact Advanced Recovery (Chocolate) Impact Advanced Recovery (Vanilla)

Note – Impact Advanced Recovery (Chocolate and Vanilla), 237 ml to be delisted 1 February 2017.

Index

Pharmaceuticals and brands

A		
Aciclovir	10	
Alanase.....	10	
Alendronate sodium with colecalciferol	8	
Amiodarone hydrochloride.....	6	
Amisulpride.....	9	
Arrow-Fluoxetine	8	
Arrow-Ornidazole	8	
B		
Beclomethasone dipropionate.....	10	
Budesonide.....	10	
Butacort Aqueous	10	
C		
Cefalexin	8	
Cephalexin ABM.....	8	
Cholecalciferol	6	
Colecalciferol	6	
Cordarone X.....	6	
D		
Dacarbazine	9	
Dapa-Tabs	6	
DBL Dacarbazine.....	9	
DBL Methotrexate Onco-Vial.....	9	
DBL Morphine Tartrate	8	
DBL Vincristine Sulfate	10	
Depo-Provera.....	7	
Dopress	8	
Dothiepin hydrochloride.....	8	
D-Penammine.....	8	
Duride.....	7	
E		
Estradot.....	8	
F		
Ferodan	6	
Ferrous sulphate	6	
Fluoxetine hydrochloride.....	8	
Fosamax Plus	8	
H		
Haloperidol	9	
High arginine oral feed 1.4 kcal/ml.....	10, 11	
Hybloc	6	
Hydrocortisone	7	
I		
Impact Advanced Recovery	10	
Impact Advanced Recovery (Chocolate)	11	
Impact Advanced Recovery (Vanilla)	11	
Indapamide	6	
Isosorbide mononitrate.....	7	
L		
Labetalol.....	6	
Levonorgestrel.....	7	
Loperamide hydrochloride.....	6	
M		
Medroxyprogesterone.....	8	
Medroxyprogesterone acetate.....	7	
Mesna	10	
Methotrexate	9	
Metoprolol - AFT CR.....	6	
Metoprolol succinate.....	6	
Mirena	7	
Mitomycin C	9	
Morphine tartrate.....	8	
Mycobutin.....	8	
N		
Nevirapine.....	8	
Nodia	6	
O		
Oestradiol	8	
Ondansetron	9	
Ondansetron Kabi.....	9	
Ornidazole.....	8	
P		
Penicillamine.....	8	
Progesterone	7	
Promethazine hydrochloride	10	
Provera	7	
Provera HD	8	
Q		
Q 300	8	
Quinine sulphate	8	
R		
Rifabutin	8	
S		
Salazopyrin	6	
Salazopyrin EN.....	6	
Serenace	9	
Sodium chloride.....	6	
Solian	9	
Solu-Cortef	7	
Sotalol	6	
Spiractin	6	
Spirolactone.....	6	
Sulphasalazine	6	
T		
Temaccord	9	
Temazolomide	9	
U		
Uromitexan	10	
Utrogestan	7	
V		
Vincristine sulphate	10	
Viramune Suspension	8	

Index

Pharmaceuticals and brands

ViruPOS	10	Vit.D3	6
---------------	----	--------------	---



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1172-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand